Menu

Martha Brumfield on the Success and Continued Growth of CPTR

How CPTR has grown into a vital and innovative catalyst in the fight against TB

Perspectives

thumb-fauci

US NIAID’s Anthony Fauci on Halting Drug Resistance

New TB drug regimens and diagnostics are needed to fight TB and MDR-TB

thumb-eichler

EMA’s Hans-Georg Eichler on Innovation Within Regulation

Instead of gatekeepers, regulators must act as enablers of innovation

thumb-mayowa

Advocate Mayowa Joel on Community Engagement

Effective and sustainable community engagement programs is a critical priority

News

CPTR-news2x-database

Host for new TB clinical trial data-sharing platform selected

TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the […]

May 4, 2015 Drug Development Press Releases clinical trials

World TB Day 2015 Supplement Profiles TB Diagnostic Landscape

Read the supplement to the Journal of Infectious Diseases called “Tuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects,” which can be found here. Madhukar Pai and Marco Schito write: “In 2015, tuberculosis remains a major global health problem, and drug-resistant tuberculosis is a growing threat. Although tuberculosis diagnosis in many countries is still reliant on older tools, […]

March 20, 2015 Drug Development RDST

From the Working Groups

Modeling & Simulation Workgroup Q2-2015 Update

Working closely with the Data Standards and Integration Workgroup (DSI-WG), the M&S-WG uses aggregated clinical trial data to create robust empirical, mechanistic, and systems biology models and quantitative simulation tools to facilitate TB drug and drug regimen development. Objectives:                                             A number of critical translational gaps exist in the science of TB drug regimen development. The […]

July 1, 2015

Data Standards & Integration Workgroup Q2-2015 Update

The DSI-WG provides the information technology (IT) infrastructure to support all CPTR data needs for developing regulatory science tools and methods to enable development of new TB drugs, drug regimens, and diagnostics. A key focus is aggregating all relevant data in a secure database for analysis by the CPTR Workgroups and authorized researchers. The DSI-WG […]

July 1, 2015

Pre-Clinical and Clinical Sciences Workgroup Q2-2015 Update

The PCS-WG is focused on the evidence-based evaluation of translational tools that support the effective decision making to advance new agents from the pre-clinical to clinical development space. These tools represent innovative approaches to address pre-clinical issues, including pre-clinical in vitro and in vivo efficacy, pre-clinical drug safety, and toxicology, pre-clinical PK/PD analyses involving the […]

July 1, 2015
About CPTR

Through partnership, CPTR speeds the development of new and markedly improved drug regimens for tuberculosis.